Comparison of BRAF inhibitor (BRAFi)-induced cutaneous squamous cell carcinoma (cuSCC) and secondary malignancies in BRAF mutation-positive metastatic melanoma (MM) patients (pts) treated with dabrafenib (D) as monotherapy or in combination with MEK1/2 inhibitor (MEKi) trametinib (T)

被引：0
|
作者：
Cebon, Jonathan S.
Flaherty, Keith
Weber, Jeffrey S.
Kim, Kevin
Infante, Jeffrey R.
Daud, Adil
Hamid, Omid
Kefford, Richard
Schuchter, Lynn Mara
Sosman, Jeffrey Alan
Sznol, Mario
Sharfman, William Howard
Gonzalez, Rene
Andrews, Miles Cameron
Dronca, Roxana Stefania
Long, Georgina
Little, Shonda M.
Sun, Peng
Patel, Kiran
McWilliams, Robert R.
机构：
[1] Ludwig Inst Canc Res, Melbourne, Vic 3050, Australia
[2] Harvard Univ, Massachusetts Gen Hosp, Ctr Canc, Sch Med, Boston, MA 02114 USA
[3] Comprehens Melanoma Res Ctr, Moffitt Canc Ctr, Tampa, FL USA
[4] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[5] Sarah Cannon Res Inst, Drug Dev Unit, Nashville, TN USA
[6] Univ Calif San Francisco, San Francisco, CA 94143 USA
[7] Angeles Clin & Res Inst, Los Angeles, CA USA
[8] Westmead Hosp, Westmead, NSW 2145, Australia
[9] Melanoma Inst Australia, Westmead, NSW, Australia
[10] Univ Penn, Philadelphia, PA 19104 USA
[11] Vanderbilt Univ, Med Ctr, Nashville, TN USA
[12] Yale Univ, New Haven, CT USA
[13] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA
[14] Univ Colorado Denver, Aurora, CO USA
[15] Ludwig Inst Canc Res, Austin Branch, Heidelberg, Vic, Australia
[16] Mayo Clin, Dept Med Oncol, Rochester, MN USA
[17] Univ Sydney, Westmead Hosp, Melanoma Inst Australia, Sydney, NSW 2006, Australia
[18] GlaxoSmithKline, Collegeville, PA USA
[19] Mayo Clin, Rochester, MN USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9016
引用
收藏
页数：1
相关论文
共 17 条
  • [1] BRAF inhibitor (BRAFi) dabrafenib in combination with the MEK1/2 inhibitor (MEKi) trametinib in BRAFi-naive and BRAFi-resistant patients (pts) with BRAF mutation-positive metastatic melanoma (MM)
    Sosman, Jeffrey Alan
    Daud, Adil
    Weber, Jeffrey S.
    Kim, Kevin
    Kefford, Richard
    Flaherty, Keith
    Infante, Jeffrey R.
    Hamid, Omid
    Cebon, Jonathan S.
    Schuchter, Lynn Mara
    McWilliams, Robert R.
    Sznol, Mario
    Sharfman, William Howard
    Algazi, Alain Patrick
    Lewis, Karl D.
    Little, Shonda M.
    Sun, Peng
    Long, Georgina
    Patel, Kiran
    Gonzalez, Rene
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [2] Efficacy, safety, and pharmacokinetics (PK) of the BRAF inhibitor dabrafenib (D) hydroxypropyl methylcellulose (HPMC) capsule formulation in combination with the MEK1/2 inhibitor trametinib (T) in patients (pts) with BRAF mutation-positive metastatic melanoma (MM)
    Schuchter, Lynn Mara
    Kudchadkar, Ragini Reiney
    Gonzalez, Rene
    Lawrence, Donald P.
    Sosman, Jeffrey Alan
    Infante, Jeffrey R.
    Daud, Adil
    Kefford, Richard
    Cebon, Jonathan S.
    Sharfman, William Howard
    Amaravadi, Ravi K.
    Boasberg, Peter D.
    Lewis, Karl D.
    Flaherty, Keith
    Ouellet, Danielle
    Little, Shonda M.
    Clark, Jennifer
    Gibney, Geoffrey Thomas
    Patel, Kiran
    Hamid, Omid
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [3] Combining targeted and immunotherapy: BRAF inhibitor dabrafenib (D) ± the MEK inhibitor trametinib (T) in combination with ipilimumab (Ipi) for V600E/K mutation-positive unresectable or metastatic melanoma (MM)
    Igor Puzanov
    Journal of Translational Medicine, 13 (Suppl 1)
  • [4] Phase II Study of the MEK1/MEK2 Inhibitor Trametinib in Patients With Metastatic BRAF-Mutant Cutaneous Melanoma Previously Treated With or Without a BRAF Inhibitor
    Kim, Kevin B.
    Kefford, Richard
    Pavlick, Anna C.
    Infante, Jeffrey R.
    Ribas, Antoni
    Sosman, Jeffrey A.
    Fecher, Leslie A.
    Millward, Michael
    McArthur, Grant A.
    Hwu, Patrick
    Gonzalez, Rene
    Ott, Patrick A.
    Long, Georgina V.
    Gardner, Olivia S.
    Ouellet, Daniele
    Xu, Yanmei
    DeMarini, Douglas J.
    Le, Ngocdiep T.
    Patel, Kiran
    Lewis, Karl D.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04) : 482 - 489
  • [5] Early tumor immune microenvironment (TME) modulation by the BRAF inhibitor (BRAFi) dabrafenib (D) and/or the MEK inhibitor (MEKi) trametinib (T) in patients (pts) with BRAF V600E/K-mutant melanoma in the COMBAT trial
    Robert, Caroline
    Shen, Shensi
    Allard, Delphine
    Fernandez, Ana Arance
    Dutriaux, Caroline
    de Jong, Egbert
    Squires, Matthew
    Grob, Jean-Jacques
    CANCER RESEARCH, 2018, 78 (13)
  • [6] Phase 1 study of the BRAF inhibitor dabrafenib (D) with or without the MEK inhibitor trametinib (T) in combination with ipilimumab (Ipi) for V600E/K mutation positive unresectable or metastatic melanoma (MM)
    Puzanov, Igor
    Callahan, Margaret K.
    Linette, Gerald P.
    Patel, Sapna Pradyuman
    Luke, Jason J.
    Sosman, Jeffrey Alan
    Wolchok, Jedd D.
    Hamid, Omid
    Minor, David R.
    Orford, Keith W.
    Hug, Bruce A.
    Ma, Bo
    Matthys, Gemma M.
    Hoos, Axel
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [7] Interim results of a phase II study of the BRAF inhibitor (BRAFi) dabrafenib (D) in combination with the MEK inhibitor trametinib (T) in patients (pts) with BRAF V600E mutated (mut) metastatic non-small cell lung cancer (NSCLC).
    Planchard, David
    Groen, Harry J. M.
    Kim, Tae Min
    Rigas, James R.
    Souquet, Pierre Jean
    Baik, Christina S.
    Barlesi, Fabrice
    Mazieres, Julien
    Quoix, Elisabeth A.
    Curtis, C. Martin
    Mookerjee, Bijoyesh
    Bartlett-Pandite, Arundathy N.
    Tucker, Christine
    D'Amelio, Anthony
    Johnson, Bruce E.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [8] Health-related quality-of-life (HRQOL) impact of dabrafenib (D) and trametinib (T) vs BRAF inhibitor (BRAFi) monotherapy by lactate dehydrogenase (LDH) in patients (pts) with BRAF V600-mutant melanoma
    Grob, J. J.
    Robert, C.
    Long, G. V.
    Stroyakovskiy, D.
    Levchenko, E.
    Chiarion-Sileni, V.
    Flaherty, K.
    Nathan, P.
    Ribas, A.
    Davies, M.
    Zhang, J.
    Chen, L.
    Mookerjee, B.
    Redhu, S.
    Schadendorf, D.
    ANNALS OF ONCOLOGY, 2016, 27
  • [9] Updated overall survival (OS) for BRF113220, a phase 1-2 study of dabrafenib (D) alone versus combined dabrafenib and trametinib (D plus T) in pts with BRAF V600 mutation-positive (+) metastatic melanoma (MM).
    Flaherty, Keith
    Daud, Adil
    Weber, Jeffrey S.
    Sosman, Jeffrey Alan
    Kim, Kevin
    Gonzalez, Rene
    Hamid, Omid
    Infante, Jeffrey R.
    Cebon, Jonathan S.
    Schuchter, Lynn Mara
    Long, Georgina V.
    Algazi, Alain Patrick
    Kudchadkar, Ragini Reiney
    Puzanov, Igor
    Lawrence, Donald P.
    Kline, Amy S.
    Cunningham, Elizabeth Ann
    Sun, Peng
    Patel, Kiran
    Kefford, Richard
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [10] Phase 1/2 study assessing the safety and efficacy of dabrafenib and trametinib combination therapy in Japanese patients with BRAF V600 mutation-positive advanced cutaneous melanoma
    Yamazaki, Naoya
    Tsutsumida, Arata
    Takahashi, Akira
    Namikawa, Kenjiro
    Yoshikawa, Shusuke
    Fujiwara, Yutaka
    Kondo, Shunsuke
    Mukaiyama, Akihira
    Zhang, Fanghong
    Kiyohara, Yoshio
    JOURNAL OF DERMATOLOGY, 2018, 45 (04): : 397 - 407
12